First-in-human phase I study of a ROR1-targeting bispecific T-cell engager (NVG-111) shows evidence of efficacy in patients with relapsed/refractory CLL and MCL

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: fe57e0bbfe4e17c7359069b4548790bd431980c3
First added on: Feb 15, 2025